<code id='394408A1F4'></code><style id='394408A1F4'></style>
    • <acronym id='394408A1F4'></acronym>
      <center id='394408A1F4'><center id='394408A1F4'><tfoot id='394408A1F4'></tfoot></center><abbr id='394408A1F4'><dir id='394408A1F4'><tfoot id='394408A1F4'></tfoot><noframes id='394408A1F4'>

    • <optgroup id='394408A1F4'><strike id='394408A1F4'><sup id='394408A1F4'></sup></strike><code id='394408A1F4'></code></optgroup>
        1. <b id='394408A1F4'><label id='394408A1F4'><select id='394408A1F4'><dt id='394408A1F4'><span id='394408A1F4'></span></dt></select></label></b><u id='394408A1F4'></u>
          <i id='394408A1F4'><strike id='394408A1F4'><tt id='394408A1F4'><pre id='394408A1F4'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:comprehensive    Page View:182
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In